Eledon Pharmaceuticals, Inc. (ELDN)
NASDAQ: ELDN · Real-Time Price · USD
4.290
-0.050 (-1.15%)
Feb 21, 2025, 4:00 PM EST - Market closed
Eledon Pharmaceuticals Employees
Eledon Pharmaceuticals had 20 employees as of December 31, 2023. The number of employees increased by 3 or 17.65% compared to the previous year.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,227,400
Market Cap
256.28M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
ELDN News
- 15 days ago - Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human - GlobeNewsWire
- 23 days ago - Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 25 days ago - Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business - Seeking Alpha
- 5 weeks ago - Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook - GlobeNewsWire
- 3 months ago - Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart - Seeking Alpha
- 4 months ago - Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 4 months ago - Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine - GlobeNewsWire